Internal Reference Number: FOI_6871
Date Request Received: 15/11/2022 00:00:00
Date Request Replied To: 29/11/2022 00:00:00
This response was sent via: By Email
Request Summary: Oesophageal and Gastric Cancer
Request Category: Researcher
| Question Number 1: Please provide the total number of patients treated in the last 3 months with any systemic anti-cancer therapy for: • Oesophageal cancer (any type or stage) • Oesophageal adenocarcinoma (any stage) • Oesophageal squamous cell carcinoma (any stage) • Gastric cancer (any type or stage) • Cancer of the gastro-oesophageal junction (any stage) | |
| Answer To Question 1: • Oesophageal cancer (any type or stage) August 2022 - <=5 September 2022 – 6 October 2022 <=5 • Oesophageal adenocarcinoma (any stage) August 2022 - <=5 September 2022 - <=5 – October 2022 0 • Oesophageal squamous cell carcinoma (any stage) August 2022 -<=5 September 2022 <=5 – October 2022 <=5 • Gastric cancer (any type or stage) August 2022 - <=5 September 2022 <=5 – October 2022 <=5 • Cancer of the gastro-oesophageal junction (any stage) August 2022 - <=5 September 2022 <=5 – October 2022 <=5 | |
| Question Number 2: How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 2: • CAPOX (Capecitabine with Oxaliplatin) 7 • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) <=5 • Lonsurf (Trifluridine - tipiracil) <=5 • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <=5 • Any other systemic anti-cancer therapy <=5 • Palliative care only <=5 | |
| Question Number 3: How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with: • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) • Nivolumab monotherapy • Nivolumab and Ipilimumab • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 3: • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) <=5 • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) <=5 • Nivolumab monotherapy 0 • Nivolumab and Ipilimumab 0 • Any other systemic anti-cancer therapy <=5 • Palliative care only <=5 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
